BioCentury
ARTICLE | Clinical News

Alagebrium: Phase II start

October 2, 2006 7:00 AM UTC

Next year, ALT will begin a double-blind, placebo-controlled, U.S. Phase II trial to improve cardiac compliance and diastolic function in about 60 aged individuals. ...